Puma Biotechnology | PBYI - Operating Expenses


Puma Biotechnology reported $49.26M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Exelixis USD 362.75M 21.35M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Glaxosmithkline GBP 7.77B 2.22B Sep/2025
Incyte USD 1.12B 3.53B Dec/2025
MacroGenics USD 67M 8M Sep/2025
Moderna USD 1.54B 259M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Takeda JPY 1.02T 400.98B Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025